Priority setting at the clinical level: the case of nusinersen and the Norwegian national expert group

BACKGROUND: Nusinersen is one of an increasing number of new, expensive orphan drugs to receive authorization. These drugs strain public healthcare budgets and challenge principles for resource allocation. Nusinersen was introduced in the Norwegian public healthcare system in 2018. A national expert...

Descripción completa

Detalles Bibliográficos
Autores principales: Magelssen, Morten, Rasmussen, Magnhild, Wallace, Sean, Førde, Reidun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094497/
https://www.ncbi.nlm.nih.gov/pubmed/33947377
http://dx.doi.org/10.1186/s12910-021-00623-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8094497/
https://www.ncbi.nlm.nih.gov/pubmed/33947377
http://dx.doi.org/10.1186/s12910-021-00623-5

Ejemplares similares